Emerging efficacy data have led to the emergency use authorization or approval of COVID-
19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded …

Background Patients with cancer are considered a priority group for Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of …

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …

Importance Patients with cancer undergoing treatment are at high risk of COVID-19 following
SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Background Patients with cancer have an increased risk of complications from SARS-CoV-2
infection. Vaccination to prevent COVID-19 is recommended, but data on the …

PURPOSE To provide real-world evidence on risks and outcomes of breakthrough COVID-
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …

Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-
2 have been approved for at least limited use, with over sixty others in clinical trials. This …

Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The
present cross-sectional online survey of adult Poles (n= 1020) expressing a willingness to …

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts
with the healthcare system, immunocompromised state from cancer or its therapies …